Opioid Use Disorder (OUD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Opioid Use Disorder (OUD) Market Outlook

Thelansis’s “Opioid Use Disorder (OUD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Opioid Use Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Opioid Use Disorder (OUD) Overview

Opioids are chemicals that can be natural, semi-synthetic, or synthetic, and they interact with the body and brain's opioid receptors to diminish the sensation of pain. While the terms opioids and opiates are often used synonymously, opiates refer exclusively to natural substances derived from the poppy plant, like morphine or heroin. Opioids, on the other hand, can be either naturally occurring or synthetically produced in laboratories. The majority of opioids are prescribed, though a significant number are also acquired illegally. It is common for patients to develop opioid dependence after using opioids for a short time, which can present as either physical or psychological dependence, or both, leading to withdrawal symptoms if the opioid use is suddenly discontinued. Opioid use disorder (OUD) can affect individuals across all educational and socioeconomic strata. OUD is more likely in patients who lack certain neurotransmitters such as dopamine, have first-degree relatives with substance abuse disorders, or have been exposed to environments where opioid use is prevalent. Risk factors also include having peers who use opioids or exposure to opioid analgesics from past injuries. Additionally, those with untreated depression, post-traumatic stress disorder, anxiety, or a history of childhood trauma are also more susceptible to developing OUD. OUD typically progresses through a continuum of opioid use. Physical dependence can develop quickly, often due to alterations in the mu-opioid receptors, such as desensitization, internalization, and signaling abnormalities. This physical dependence is also a critical factor in the withdrawal symptoms experienced when opioid use is abruptly ceased, reinforcing both the continuation and cessation of opioid use. A diagnosis of OUD is made when an individual's ongoing use of opioids causes significant impairment or distress, which can manifest as difficulties in controlling opioid use and intense cravings for the drug. The treatment of OUD not only improves physical and psychological health but also reduces the likelihood of overdose, criminal behavior, and subsequent penalties. Treatment strategies include a variety of rehabilitation approaches that begin with cognitive behavioral techniques similar to those used for other chronic conditions. Medication-assisted treatment (MAT), including opioid replacement, maintenance, or substitution therapy under medical supervision, utilizes safer opioid alternatives. Such treatments, including outpatient buprenorphine office therapy (OBOT), help reduce withdrawal symptoms, diminish cravings, and minimize or eliminate euphoria. These therapeutic strategies are essential in managing and maintaining recovery in patients with OUD.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: